Becquemin Jean-Pierre, Allaire Eric, Desgranges Pascal, Kobeiter Hischam
Department of Vascular Surgery, Henri Mondor Hospital AP/HP Paris, University Paris XII, Creteil, France.
Tech Vasc Interv Radiol. 2005 Mar;8(1):30-40. doi: 10.1053/j.tvir.2005.03.011.
More than a decade after the first clinical attempts, two large randomized studies have proven that endovascular aortic aneurysm repair (EVAR) provides immediate advantages over open repair. In the long run, however, a relatively high number of reinterventions is necessary to improve the long-term efficacy of EVAR, which may outweigh the early benefits. Since EVAR is gaining popularity in the medical community and in patients with abdominal aortic aneurysm (AAA), it is expected that a growing number of patients will present with delayed complications requiring some kind of reinterventions. For the patient's safety, vascular surgeons and interventional radiologists involved in EVAR must be well aware of these complications and the ways to overcome them. We began our endovascular program for AAA in 1994 and currently follow 485 patients with a variety of manufactured grafts. In this article we describe the delayed complications observed with EVAR, their mechanisms, favoring factors, and ways to treat them.
在首次临床尝试十多年后,两项大型随机研究已证明,血管内主动脉瘤修复术(EVAR)相较于开放修复术具有即时优势。然而,从长远来看,为提高EVAR的长期疗效,需要进行相对大量的再次干预,而这可能会超过早期的益处。由于EVAR在医学界和腹主动脉瘤(AAA)患者中越来越受欢迎,预计将会有越来越多的患者出现需要某种再次干预的延迟并发症。为了患者的安全,参与EVAR的血管外科医生和介入放射科医生必须充分了解这些并发症及其克服方法。我们于1994年开始了针对AAA的血管内治疗项目,目前随访485例使用各种人造移植物的患者。在本文中,我们描述了EVAR观察到的延迟并发症、其机制、促成因素以及治疗方法。